Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26‐Week Results From the Phase 3 PaTHway Trial

por Khan, Aliya A, Rubin, Mishaela R, Schwarz, Peter, Vokes, Tamara, Shoback, Dolores M, Gagnon, Claudia, Palermo, Andrea, Marcocci, Claudio, Clarke, Bart L, Abbott, Lisa G, Hofbauer, Lorenz C, Kohlmeier, Lynn, Pihl, Susanne, An, Xuebei, Eng, Walter Frank, Smith, Alden R, Ukena, Jenny, Sibley, Christopher T, Shu, Aimee D, Rejnmark, Lars
Publicado 2022

OR23-05 Log-term Efficacy And Safety Of Transcon PTH In Adults With Hypoparathyroidism: 52-week Results From The Open-label Extension Of The Phase 3 Pathway Trial

por Clarke, Bart, Aziz Khan, Aliya, Ruth Rubin, Mishaela, Schwarz, Peter E, Vokes, Tamara J, Shoback, Dolores M, Gagnon, Claudia, Palermo, Andrea, Abbott, Lisa G, Hofbauer, Lorenz C, Kohlmeier, Lynn, Cetani, Filomena, Phil, Susanne, An, Xuebei, Raymond Smith, Alden, Lai, Bryant, Le, John, Ukena, Jenny, Sibley, Christopher, Shu, Aimee, Rejnmark, Lars
Publicado 2023